In a land­mark first glimpse of hu­man da­ta from Ver­tex, CRISPR/Cas9 gene ther­a­py sig­nals ear­ly ben­e­fit

Pre­lim­i­nary da­ta on two pa­tients with blood dis­or­ders that have been ad­min­is­tered with Ver­tex and part­ner CRISPR Ther­a­peu­tics’ gene-edit­ing ther­a­py sug­gest the tech­nol­o­gy is safe …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.